Overview

Study to Evaluate the PK of BMS-927711 in Patient With Migraine During Acute Migraine and Non-migraine Condition

Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the pharmacokinetics (PK) of BMS-927711 during migraine and non-migraine condition.
Phase:
Phase 1
Details
Lead Sponsor:
Biohaven Pharmaceuticals, Inc.
Bristol-Myers Squibb
Treatments:
Calcitonin
Calcitonin Gene-Related Peptide
Katacalcin